On July 24, 2026, oncology clinical societies in Australia released clinical guidelines emphasizing the role of early immune checkpoint inhibition in preventing tumor recurrence. Securing authentic immunotherapies like Keytruda (Pembrolizumab) 100mg Injection is a vital need for Australian patients undergoing treatment for advanced melanoma, non-small cell lung cancer, and other solid tumors.

At Critical Kare Pharma, we specialize in delivering authentic, cold-chain monitored biological treatments to patients and oncology clinics across Australia. Sourcing original checkpoint inhibitors ensures clinical reliability and peace of mind.

Therapeutic Profile of Pembrolizumab

• Immune System Activation: Pembrolizumab is a selective monoclonal antibody that blocks the PD-1 pathway, enabling the body's own T-cells to recognize and attack malignant cells.
• Broad Clinical Indications: Approved for a wide range of indications including advanced melanoma, NSCLC, head and neck squamous cell carcinoma, and MSI-H tumors.
• How to Use & Administer: Administered as an intravenous (IV) infusion over 30 minutes, typically every 3 or 6 weeks. Reconstitution and dilution must be conducted by qualified healthcare providers in a sterile clinic environment.
• Precise Cold-Chain Sourcing: Must be refrigerated at 2°C to 8°C. Do not freeze, shake, or expose to direct sunlight.

TGA Personal Importation Scheme Sourcing

Australian residents can legally import up to a 3-month supply of registered or unregistered prescription medicines for personal use under the TGA Personal Importation Scheme. Critical Kare Pharma facilitates this process by preparing all required customs paperwork and maintaining a fully verified 2–8°C cold-chain from our logistics centers to clinical facilities in Sydney, Melbourne, and regional Australia.